Nektar (NKTR) will be regaining the full rights to Rezpeg from Eli Lilly (LLY). Nektar plans to move forward with Rezpeg and will initiate a Phase 2b study in patients with moderate-to-severe atopic dermatitis in 2023. The company will also explore other auto-immune indications for the development plan for Rezpeg. Rezpeg evidenced a dose-dependent improvement over placebo for key efficacy measures of mean change in EASI, EASI-75, vIGA-AD scores, and Itch NRS greater than or equal to4-point scales. These improvements were observed for an additional 36 weeks following the 12-week treatment period.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NKTR:
- Nektar Chief Medical Officer Brian Kotzin, CFO Jillian Thomsen to step down
- Nektar announces strategic repriotization, to reduce San Francisco staff by 60%
- Nektar Therapeutics says no cash deposits, securities at Silicon Valley Bank
- Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
- Nektar reports Q4 EPS (32c), consensus (45c)